1
00:00:00,120 --> 00:00:01,080
Speaker 1: How's San Francisco.

2
00:00:01,920 --> 00:00:03,080
Speaker 2: It's uh, it's great.

3
00:00:03,120 --> 00:00:04,960
Speaker 3: You know, like I think that a lot of people

4
00:00:04,960 --> 00:00:07,520
Speaker 3: told me it was going to be a dystopian healscape

5
00:00:07,600 --> 00:00:09,080
Speaker 3: and it's not.

6
00:00:09,920 --> 00:00:12,040
Speaker 1: Wait, it's the first time you've actually gone right to

7
00:00:12,080 --> 00:00:14,200
Speaker 1: the JP Morgan healthcare conference.

8
00:00:14,720 --> 00:00:18,360
Speaker 2: To this one. Yeah, the specific conference, And what's.

9
00:00:18,160 --> 00:00:20,520
Speaker 1: Your first impression of it? I guess is there anything

10
00:00:20,520 --> 00:00:21,280
Speaker 1: that surprised you.

11
00:00:21,400 --> 00:00:24,040
Speaker 2: I guess what really surprised me was the security.

12
00:00:24,280 --> 00:00:26,599
Speaker 3: Like I've been to conferences before where it's kind of

13
00:00:26,640 --> 00:00:29,200
Speaker 3: like you can't even go into the hotel without like

14
00:00:29,280 --> 00:00:31,360
Speaker 3: your past and they're really strict about it. So I

15
00:00:31,360 --> 00:00:34,519
Speaker 3: guess that was the most surprising thing. But other than that,

16
00:00:34,600 --> 00:00:38,000
Speaker 3: it's you know, the meetings are cool. Conference, It's still

17
00:00:38,040 --> 00:00:39,720
Speaker 3: a conference, right, Like, it's not I'm not going to

18
00:00:39,800 --> 00:00:42,159
Speaker 3: be like, oh god, this is you know, the coolest

19
00:00:42,159 --> 00:00:44,599
Speaker 3: thing I've ever seen in my life, although that did

20
00:00:44,680 --> 00:00:47,040
Speaker 3: kind of happen here with there was a company that

21
00:00:47,120 --> 00:00:49,879
Speaker 3: was presenting that has I guess like you can call

22
00:00:49,880 --> 00:00:53,080
Speaker 3: it like drug GPT, right, it's like artificial intelligence but

23
00:00:53,200 --> 00:00:56,680
Speaker 3: used to like find new drugs, and that was really cool.

24
00:00:59,400 --> 00:01:00,760
Speaker 4: I did a left one.

25
00:01:02,080 --> 00:01:07,959
Speaker 1: Jimmy Okay, Simony up barges, this isn't After School Special,

26
00:01:08,000 --> 00:01:10,720
Speaker 1: except I've decided I'm going to base my entire personality

27
00:01:10,720 --> 00:01:13,720
Speaker 1: going forward on campaigning for a strategic pork reserve in

28
00:01:13,760 --> 00:01:14,200
Speaker 1: the US.

29
00:01:14,280 --> 00:01:16,000
Speaker 4: Where's the best with imposta?

30
00:01:16,200 --> 00:01:18,759
Speaker 1: These are the important question? Is that robots taking over

31
00:01:18,800 --> 00:01:19,399
Speaker 1: the world. No.

32
00:01:19,480 --> 00:01:22,360
Speaker 4: I think that like in a couple of years, the

33
00:01:22,440 --> 00:01:24,640
Speaker 4: AI will do a really good job of making the

34
00:01:24,640 --> 00:01:27,880
Speaker 4: odd Lots podcast and people to say, I don't really

35
00:01:27,920 --> 00:01:29,800
Speaker 4: need to listen to Joe and Tracy anymore.

36
00:01:30,000 --> 00:01:30,600
Speaker 2: We do have.

37
00:01:32,720 --> 00:01:36,680
Speaker 1: Perfect You're listening to lots More where we catch up

38
00:01:36,680 --> 00:01:39,560
Speaker 1: with friends about what's going on right now, because.

39
00:01:39,280 --> 00:01:42,319
Speaker 4: Even when odd Lots is over, there's always lots more.

40
00:01:42,560 --> 00:01:46,240
Speaker 1: And we really do have the perfect guest. We're talking

41
00:01:46,280 --> 00:01:50,200
Speaker 1: to James Van Gelan of saitriniresearch dot com, also known

42
00:01:50,200 --> 00:01:52,880
Speaker 1: as Satrini on Twitter. You might remember him. We had

43
00:01:52,920 --> 00:01:56,080
Speaker 1: him on odd Thloughts back in August to talk about

44
00:01:56,280 --> 00:01:59,680
Speaker 1: weight loss drugs, including ozembic and how they were going

45
00:01:59,720 --> 00:02:03,440
Speaker 1: to chat everything. That was kind of a prescient conversation,

46
00:02:03,800 --> 00:02:07,360
Speaker 1: I think because since then we've seen even more excitement

47
00:02:07,400 --> 00:02:09,280
Speaker 1: for a lot of these drugs and the stocks have

48
00:02:09,320 --> 00:02:13,240
Speaker 1: taken off even more, James, is that what everyone's talking

49
00:02:13,320 --> 00:02:14,440
Speaker 1: about at that conference?

50
00:02:15,000 --> 00:02:17,360
Speaker 3: I think it's it's split kind of fifty to fifty

51
00:02:17,440 --> 00:02:21,920
Speaker 3: between the GLP one drugs and then the ADC cancer

52
00:02:21,960 --> 00:02:25,239
Speaker 3: stuff because of the side of Kinetics acquisition that was announced.

53
00:02:25,919 --> 00:02:29,760
Speaker 4: I don't like going to conferences. Typically, you know, everyone

54
00:02:29,800 --> 00:02:31,880
Speaker 4: licet in a while, they're okay, But what is like,

55
00:02:32,120 --> 00:02:34,840
Speaker 4: I know, like the JP Morgan Healthcare Conference. I know

56
00:02:34,880 --> 00:02:36,480
Speaker 4: it's a big deal. Why is it such a big deal?

57
00:02:36,520 --> 00:02:39,239
Speaker 4: What is it exactly? And like why this one in particular,

58
00:02:39,280 --> 00:02:41,640
Speaker 4: how did it become like such an important event for

59
00:02:41,720 --> 00:02:42,600
Speaker 4: healthcare investors.

60
00:02:42,960 --> 00:02:45,120
Speaker 2: I don't know the history of the conference, but when

61
00:02:45,160 --> 00:02:48,760
Speaker 2: you look at the agenda speaking here, it's you know,

62
00:02:48,840 --> 00:02:51,359
Speaker 2: everyone that's a big deal. Everyone that you would want

63
00:02:51,400 --> 00:02:53,720
Speaker 2: to know what they're doing, they're kind of here. I

64
00:02:53,760 --> 00:02:56,480
Speaker 2: think that there's even more value in just sitting in

65
00:02:56,560 --> 00:02:59,040
Speaker 2: some of the hotel bars, like over hearing how.

66
00:02:58,960 --> 00:03:02,359
Speaker 3: People are talking, you know, like people seem pretty optimistic

67
00:03:02,440 --> 00:03:04,960
Speaker 3: on like med tech in the funding environment, and that's

68
00:03:05,120 --> 00:03:07,920
Speaker 3: almost more valuable to me than the conference itself.

69
00:03:08,320 --> 00:03:11,560
Speaker 4: So, by the way, we're recording this January tenth, Novo

70
00:03:11,680 --> 00:03:15,799
Speaker 4: Nordisk hitting yet another all time high right now. It's

71
00:03:15,919 --> 00:03:19,040
Speaker 4: kind of crazy, Tracy, Like, for all of the hype

72
00:03:19,480 --> 00:03:23,520
Speaker 4: about the GLP one drugs, A, the stocks keep going

73
00:03:23,600 --> 00:03:26,920
Speaker 4: higher and B. I feel like every day there's some

74
00:03:27,000 --> 00:03:29,919
Speaker 4: other article or thing about here's another thing that they

75
00:03:29,960 --> 00:03:33,720
Speaker 4: do well, or another area that we're researching that shows

76
00:03:33,760 --> 00:03:36,120
Speaker 4: promise where it's not just about weight less, you know,

77
00:03:36,160 --> 00:03:39,360
Speaker 4: like compulsion or other things. Like it's pretty wild how

78
00:03:39,400 --> 00:03:40,520
Speaker 4: this is not slowing down.

79
00:03:40,760 --> 00:03:44,080
Speaker 1: This is my opportunity to reject the idea of the

80
00:03:44,160 --> 00:03:47,040
Speaker 1: all thoughts curse. Oh and that we top tech a

81
00:03:47,080 --> 00:03:50,040
Speaker 1: lot of these things. We did not top tick Nova

82
00:03:50,080 --> 00:03:51,920
Speaker 1: Nordisk stock. Okay, we were a.

83
00:03:51,880 --> 00:03:53,320
Speaker 4: Launch that we haven't top ticked.

84
00:03:53,480 --> 00:03:54,360
Speaker 2: Yeah.

85
00:03:54,440 --> 00:03:57,280
Speaker 3: Actually, I actually I actually when I got the invite

86
00:03:57,280 --> 00:04:00,320
Speaker 3: to come back, I remember everyone that was like, if

87
00:04:00,360 --> 00:04:02,240
Speaker 3: you go on a podcast and you talk about this trend,

88
00:04:02,320 --> 00:04:04,880
Speaker 3: like that's it, it's over, you know. So when I

89
00:04:04,880 --> 00:04:06,360
Speaker 3: got the invite to come back, I went and I

90
00:04:06,440 --> 00:04:09,640
Speaker 3: looked at like Lily and Novo and yeah, so I

91
00:04:09,680 --> 00:04:12,600
Speaker 3: think it's like eighty one percent of the time they

92
00:04:12,600 --> 00:04:17,040
Speaker 3: have been at all time highs since. Yeah, since that's so,

93
00:04:17,480 --> 00:04:19,920
Speaker 3: I think we can put the odlus course rum or two.

94
00:04:20,160 --> 00:04:22,320
Speaker 4: We're not trying to time the market. We're not here

95
00:04:22,360 --> 00:04:26,280
Speaker 4: to make recommendations, but we are just trying to establish

96
00:04:26,520 --> 00:04:29,560
Speaker 4: that not every time we talk about a trend it's

97
00:04:29,600 --> 00:04:31,440
Speaker 4: at the top. And I'll just say the other one.

98
00:04:31,920 --> 00:04:35,080
Speaker 4: We've done multiple episodes over the years, over the last

99
00:04:35,120 --> 00:04:38,680
Speaker 4: year relating to in Nvidia and semiconductors and Tracy and

100
00:04:38,720 --> 00:04:41,760
Speaker 4: Nvidia at another all time high today. So we're just

101
00:04:41,800 --> 00:04:42,839
Speaker 4: getting these on the record.

102
00:04:42,880 --> 00:04:44,800
Speaker 1: We're just journalists who want to be timely.

103
00:04:44,920 --> 00:04:46,960
Speaker 4: We're just journalists who want to be We just we

104
00:04:47,120 --> 00:04:50,080
Speaker 4: just want to be timely. Okay, So within the GLP

105
00:04:50,240 --> 00:04:54,680
Speaker 4: one world, what's hot? What are people talking about? What's

106
00:04:54,760 --> 00:04:56,839
Speaker 4: interesting within GLP ones?

107
00:04:57,279 --> 00:04:59,240
Speaker 2: Well, there's there's two main things. Right.

108
00:04:59,279 --> 00:05:03,920
Speaker 3: You got the oral drugs, and like Lily's CEO had

109
00:05:03,960 --> 00:05:06,359
Speaker 3: a fireside chat type thing, and.

110
00:05:06,400 --> 00:05:07,560
Speaker 2: I have this big realization.

111
00:05:07,680 --> 00:05:09,720
Speaker 3: I don't know if this was like common knowledge among

112
00:05:09,760 --> 00:05:11,600
Speaker 3: people that are healthcare specialists, but I had a big

113
00:05:11,640 --> 00:05:15,479
Speaker 3: realization that basically, with these oral drugs, it's not so

114
00:05:15,600 --> 00:05:18,760
Speaker 3: much about the fact that like patients don't want to

115
00:05:18,880 --> 00:05:21,560
Speaker 3: use these auto injectors, because as we've seen, people are

116
00:05:21,560 --> 00:05:25,400
Speaker 3: pretty much fine with the auto injectors. The thing is,

117
00:05:25,440 --> 00:05:30,240
Speaker 3: the auto injectors are super expensive and like very fight constrained,

118
00:05:30,760 --> 00:05:34,120
Speaker 3: so it's kind of like the oral drug, right, Like

119
00:05:34,200 --> 00:05:38,320
Speaker 3: it's very easy to make a pill, and the high.

120
00:05:38,240 --> 00:05:41,080
Speaker 2: Chain is like not the same as the auto injector.

121
00:05:41,160 --> 00:05:43,359
Speaker 3: So it turns out the way that he was speaking,

122
00:05:43,360 --> 00:05:48,240
Speaker 3: it really gave me the idea that like these oral drugs, right,

123
00:05:48,279 --> 00:05:51,160
Speaker 3: like Lily has orf and Novo has one too that's

124
00:05:51,200 --> 00:05:53,760
Speaker 3: in the in the works, and they seem to be

125
00:05:54,040 --> 00:05:55,279
Speaker 3: kind of like the rate limitter.

126
00:05:55,400 --> 00:05:55,560
Speaker 2: Right.

127
00:05:55,640 --> 00:05:58,760
Speaker 3: He had something that he said about how he sees

128
00:05:59,040 --> 00:06:01,880
Speaker 3: supply for these drugs being a constraint for you know,

129
00:06:02,000 --> 00:06:05,120
Speaker 3: the next ten years, and then he said, that's not

130
00:06:05,200 --> 00:06:08,360
Speaker 3: a bad thing, right, because we have you know, half

131
00:06:08,440 --> 00:06:10,920
Speaker 3: of we have I don't know, five hundred thousand people

132
00:06:11,240 --> 00:06:13,800
Speaker 3: in the US that are on these drugs and one

133
00:06:13,880 --> 00:06:15,159
Speaker 3: hundred and ten million.

134
00:06:14,880 --> 00:06:17,880
Speaker 2: People that theoretically could or should take them.

135
00:06:18,360 --> 00:06:23,159
Speaker 3: And that doesn't even count in Brazil or China or India.

136
00:06:23,320 --> 00:06:24,839
Speaker 2: Right, that's the main thing.

137
00:06:25,680 --> 00:06:28,360
Speaker 1: So one of the things that lives rent free in

138
00:06:28,400 --> 00:06:30,960
Speaker 1: my head ever since we first spoke to you was

139
00:06:31,320 --> 00:06:35,960
Speaker 1: Titan Stapler. Do you remember that, like this this company

140
00:06:35,960 --> 00:06:39,640
Speaker 1: that makes Titan stomach staplers, and I'm wondering, you know,

141
00:06:39,680 --> 00:06:42,960
Speaker 1: obviously people are talking about the sort of positive impact

142
00:06:43,520 --> 00:06:46,359
Speaker 1: of weight loss drugs GLP one on their bottom lines,

143
00:06:46,360 --> 00:06:48,440
Speaker 1: but is there anyone at the conference that you've heard

144
00:06:48,600 --> 00:06:50,880
Speaker 1: or seen talking about negative impact?

145
00:06:51,720 --> 00:06:55,919
Speaker 3: Honestly, I think that ever since right around the first

146
00:06:55,920 --> 00:06:59,040
Speaker 3: time we spoke, there was a wave of some people

147
00:06:59,080 --> 00:07:01,200
Speaker 3: that fell on the soul, so to speak, kind of

148
00:07:01,240 --> 00:07:04,840
Speaker 3: like how CHEG did with artificial intelligence. I think that

149
00:07:05,279 --> 00:07:07,599
Speaker 3: once they saw the stock reactions, once you come out

150
00:07:07,839 --> 00:07:10,760
Speaker 3: and you say, you know, GLP one drugs are killing us,

151
00:07:10,840 --> 00:07:13,400
Speaker 3: and then your stock goes down ten percent a day,

152
00:07:13,440 --> 00:07:16,040
Speaker 3: I think they're a little more careful about it now,

153
00:07:16,280 --> 00:07:20,200
Speaker 3: they're not readily offering that information. But also at the

154
00:07:20,240 --> 00:07:24,600
Speaker 3: same time, some obviously I had a very like high

155
00:07:24,600 --> 00:07:28,720
Speaker 3: conviction thesis on the idea that you know, sepath machines

156
00:07:29,000 --> 00:07:32,679
Speaker 3: and the Titan stapler and all these things would actively affected.

157
00:07:32,760 --> 00:07:36,680
Speaker 3: But it got so priced in so quickly, and some

158
00:07:36,760 --> 00:07:39,280
Speaker 3: of that was not GLP one stuff, right, Some of

159
00:07:39,280 --> 00:07:42,920
Speaker 3: that was basically just rates, Like don't attribute to GLP

160
00:07:43,000 --> 00:07:45,080
Speaker 3: one's what you can attribute to interest rates. I guess

161
00:07:45,160 --> 00:07:48,040
Speaker 3: and so I think with Medtech where it is, it's

162
00:07:48,120 --> 00:07:51,480
Speaker 3: kind of even with the impact there, they can kind

163
00:07:51,480 --> 00:07:53,680
Speaker 3: of say, okay, you know, but it's a little bit

164
00:07:53,720 --> 00:07:54,560
Speaker 3: better than you've heared.

165
00:07:55,240 --> 00:07:59,160
Speaker 4: Res Med a big maker of CPAP machines that's bounced

166
00:07:59,160 --> 00:08:01,200
Speaker 4: a little bit over the last few months. Those still

167
00:08:01,240 --> 00:08:02,640
Speaker 4: down from where it was a year ago.

168
00:08:02,920 --> 00:08:03,080
Speaker 2: You know.

169
00:08:03,160 --> 00:08:05,600
Speaker 4: I was walking back to the office from lunch today

170
00:08:05,640 --> 00:08:08,760
Speaker 4: and I saw a sign for weight Watchers about like

171
00:08:09,040 --> 00:08:12,640
Speaker 4: get on their GLP one program. So obviously they're trying

172
00:08:12,640 --> 00:08:15,280
Speaker 4: to like pivot to being a GLP one player, show

173
00:08:15,320 --> 00:08:17,600
Speaker 4: how they can fit in. But that's stock not doing

174
00:08:17,640 --> 00:08:17,960
Speaker 4: so well.

175
00:08:18,000 --> 00:08:19,920
Speaker 2: It's down.

176
00:08:20,680 --> 00:08:20,880
Speaker 1: Yeah.

177
00:08:22,440 --> 00:08:22,680
Speaker 2: Yeah.

178
00:08:22,840 --> 00:08:24,800
Speaker 3: Brown Trip went up like one hundred and fifty percent

179
00:08:24,840 --> 00:08:27,280
Speaker 3: then went all the way down. And the thing if

180
00:08:27,280 --> 00:08:29,400
Speaker 3: you're in the GLP one space at all and Eli

181
00:08:29,440 --> 00:08:32,280
Speaker 3: Lilly starts doing what you're doing, it's not great.

182
00:08:33,640 --> 00:08:35,200
Speaker 2: Tracy, Tracy.

183
00:08:35,240 --> 00:08:36,920
Speaker 4: I feel like investors, you know, they love to get

184
00:08:36,960 --> 00:08:39,000
Speaker 4: cute with things like I missed the Eli Lily trace

185
00:08:39,360 --> 00:08:41,440
Speaker 4: by this other company, and then you see, like you know,

186
00:08:41,520 --> 00:08:44,520
Speaker 4: in videos, the winners so far been the winner, Novo's

187
00:08:44,520 --> 00:08:47,000
Speaker 4: the winner Lily, and then all these other like secondary

188
00:08:47,080 --> 00:08:49,080
Speaker 4: tertiary plays. It's like kind of dice here.

189
00:08:49,400 --> 00:08:52,760
Speaker 1: Yeah, James, you mentioned something else that I think is

190
00:08:52,840 --> 00:08:54,880
Speaker 1: kind of like a big factor here, which is just

191
00:08:55,080 --> 00:08:57,600
Speaker 1: interest rates and the move we've seen there. And you

192
00:08:57,679 --> 00:09:01,960
Speaker 1: mentioned everyone being sort of enthusiastic about funding availability for

193
00:09:02,120 --> 00:09:05,520
Speaker 1: pharma going into twenty twenty four. How much is some

194
00:09:05,600 --> 00:09:09,480
Speaker 1: of this excitement just a pure rates play on the

195
00:09:09,520 --> 00:09:11,960
Speaker 1: cost of funding for you know, these companies that spend

196
00:09:11,960 --> 00:09:14,800
Speaker 1: a lot of money on research and development actually coming down.

197
00:09:15,200 --> 00:09:17,760
Speaker 3: I think it's like a rate of change thing, right.

198
00:09:18,080 --> 00:09:22,719
Speaker 3: It got so bad that even an incremental improvement is

199
00:09:22,760 --> 00:09:26,040
Speaker 3: going to be met with overwhelming kind of enthusiasm. Enthusiasm

200
00:09:26,200 --> 00:09:29,520
Speaker 3: because the regional bank stuff, you know, Silicon Valley Bank

201
00:09:29,559 --> 00:09:34,560
Speaker 3: collapsing hurt the biopharma and biotech industry significantly. And I

202
00:09:34,600 --> 00:09:36,960
Speaker 3: think that it's kind of been so long where rates

203
00:09:36,960 --> 00:09:39,120
Speaker 3: were just going up and everything's going to stay higher

204
00:09:39,160 --> 00:09:41,800
Speaker 3: for longer, and now you know, there's a glimmer of

205
00:09:41,840 --> 00:09:45,320
Speaker 3: hope on the horizon. And it's very easy if you're

206
00:09:45,360 --> 00:09:47,920
Speaker 3: in this industry and you've just been hearing no for

207
00:09:47,960 --> 00:09:51,360
Speaker 3: the past you know, year and a half, to say, oh, finally, you.

208
00:09:51,320 --> 00:10:06,920
Speaker 4: Know, wait, can we go back? I think you said

209
00:10:06,920 --> 00:10:09,360
Speaker 4: there were like two things in the GLP one space.

210
00:10:09,360 --> 00:10:11,640
Speaker 4: You mentioned auto injectors, and so I was curious what

211
00:10:11,679 --> 00:10:12,360
Speaker 4: the other one was.

212
00:10:12,760 --> 00:10:17,040
Speaker 3: The other thing is that we're kind of finding out, right,

213
00:10:17,080 --> 00:10:20,160
Speaker 3: I guess we already knew. But the thing with the

214
00:10:20,240 --> 00:10:23,640
Speaker 3: GLP one drugs is that they will make you lose weight, right,

215
00:10:23,720 --> 00:10:28,280
Speaker 3: and if you are morbidly obese, that's great. Now, the

216
00:10:28,400 --> 00:10:32,040
Speaker 3: problem is you are going to lose some muscle too.

217
00:10:32,160 --> 00:10:35,199
Speaker 3: Right when you say you lose weight, it's not necessarily

218
00:10:35,200 --> 00:10:37,920
Speaker 3: that all that weight is fat, and that can be

219
00:10:37,920 --> 00:10:40,600
Speaker 3: a problem just because kind of common sense, right, it's

220
00:10:40,600 --> 00:10:43,920
Speaker 3: better to have muscle mass. Muscle mass is great, especially

221
00:10:43,920 --> 00:10:48,160
Speaker 3: if you're diabetic, and also from like a cosmetic aesthetics perspective.

222
00:10:48,440 --> 00:10:51,640
Speaker 3: So now kind of the thing that everyone is focusing

223
00:10:51,679 --> 00:10:56,319
Speaker 3: on is finding a combination drug to be used alongside

224
00:10:56,480 --> 00:10:59,640
Speaker 3: these GLP WANs that makes it so that you either

225
00:10:59,679 --> 00:11:02,280
Speaker 3: do not lose muscle when you are losing fat, or

226
00:11:02,280 --> 00:11:05,440
Speaker 3: that you actually gain muscle. So there was some data

227
00:11:05,480 --> 00:11:09,160
Speaker 3: from Regeneron that was, in my opinion, just like everything

228
00:11:09,160 --> 00:11:13,080
Speaker 3: else that happens, very bullish. For Lily, they had an acquisition.

229
00:11:13,559 --> 00:11:18,040
Speaker 3: They bought Versatus for four billion dollars and Versatus has

230
00:11:18,040 --> 00:11:21,000
Speaker 3: a drug called the migramat and when you combine the

231
00:11:21,080 --> 00:11:22,319
Speaker 3: migramat with you.

232
00:11:22,240 --> 00:11:24,840
Speaker 2: Know, semaglue tide or another GLP one drug.

233
00:11:25,480 --> 00:11:28,240
Speaker 3: The phase one trial was showing that you will lose

234
00:11:28,440 --> 00:11:31,400
Speaker 3: twelve percent of your body weight, but you will also

235
00:11:31,520 --> 00:11:34,560
Speaker 3: increase your lean muscle mass by six percent, which is

236
00:11:34,920 --> 00:11:37,959
Speaker 3: a cheap code, right, Like there is nobody doesn't want

237
00:11:37,960 --> 00:11:39,640
Speaker 3: to lose ten percent of their body weight and then

238
00:11:39,679 --> 00:11:44,320
Speaker 3: also gain lean muscle mass. It's also very important with

239
00:11:44,400 --> 00:11:47,600
Speaker 3: like the elderly population, you know, because they if they

240
00:11:47,640 --> 00:11:51,479
Speaker 3: get weaker, then they're more at risk for falls or injuries,

241
00:11:51,520 --> 00:11:54,000
Speaker 3: and you know, making sure that like bone mineral density

242
00:11:54,040 --> 00:11:56,160
Speaker 3: stays high, so you know, but at the same time,

243
00:11:56,200 --> 00:11:58,120
Speaker 3: it's also if you make the drug that seems like

244
00:11:58,120 --> 00:11:58,959
Speaker 3: a money printer to me.

245
00:11:59,600 --> 00:12:03,560
Speaker 1: Well, so I think muscle building drugs already exist in

246
00:12:03,600 --> 00:12:06,600
Speaker 1: the form of anabolic steroids, although I doubt anyone's recommending

247
00:12:07,160 --> 00:12:09,079
Speaker 1: recommending that you go on a zempic and then take

248
00:12:09,120 --> 00:12:12,480
Speaker 1: steroids as well. But James, you mentioned at the very

249
00:12:12,480 --> 00:12:15,280
Speaker 1: beginning of this conversation that you saw something cool and

250
00:12:15,880 --> 00:12:18,920
Speaker 1: you sent me a little video of this and when

251
00:12:18,920 --> 00:12:20,520
Speaker 1: you send me the video, I had a sort of

252
00:12:20,679 --> 00:12:23,719
Speaker 1: realization that we are truly in the future in some

253
00:12:23,800 --> 00:12:26,439
Speaker 1: respects because you sent me a video of a presentation

254
00:12:27,280 --> 00:12:32,040
Speaker 1: of basically like an AI for drug development, so drug GPT,

255
00:12:32,640 --> 00:12:36,360
Speaker 1: and you recorded the video using your meta sunglasses.

256
00:12:36,640 --> 00:12:39,000
Speaker 3: I'm speaking to you guys right now on them. It

257
00:12:39,080 --> 00:12:43,360
Speaker 3: was definitely future coded for sure. I mean the thing was,

258
00:12:43,600 --> 00:12:47,600
Speaker 3: this was Recursion Pharma's presentation and theirs was at you know,

259
00:12:47,720 --> 00:12:50,280
Speaker 3: seven fifteen in the morning, so it wasn't very crowded,

260
00:12:50,320 --> 00:12:53,880
Speaker 3: and then Nvidio presented later, but Recursion was the one

261
00:12:53,880 --> 00:12:56,240
Speaker 3: that had the demo. They did it right in front

262
00:12:56,240 --> 00:12:58,520
Speaker 3: of you. It's like if you loaded up Chatgypt and

263
00:12:58,559 --> 00:13:01,480
Speaker 3: started asking you questions, but they where they It's called

264
00:13:01,559 --> 00:13:04,640
Speaker 3: low I call it drug GPT just because it's funny.

265
00:13:04,720 --> 00:13:09,480
Speaker 3: But they opened up this program and then started they said,

266
00:13:09,520 --> 00:13:11,880
Speaker 3: you know, give us a list of molecules that are

267
00:13:11,920 --> 00:13:16,000
Speaker 3: gonna target RAF one or and it just gave him

268
00:13:16,120 --> 00:13:19,000
Speaker 3: fifty new drugs and then they can refine it down

269
00:13:19,040 --> 00:13:21,680
Speaker 3: based on how likely it is to have this side

270
00:13:21,679 --> 00:13:24,040
Speaker 3: effect or that side effect, or where the structural activity

271
00:13:24,080 --> 00:13:28,080
Speaker 3: relationship is or you know, the dose response curve just

272
00:13:28,120 --> 00:13:30,679
Speaker 3: based on you know, this predictive.

273
00:13:30,360 --> 00:13:36,520
Speaker 2: AI and how do we know well, I mean, how

274
00:13:36,559 --> 00:13:37,760
Speaker 2: do we know that the problem?

275
00:13:37,840 --> 00:13:39,640
Speaker 4: Yeah, I mean like so like they like they give

276
00:13:39,679 --> 00:13:42,200
Speaker 4: you some molecules and stuff, but like, how does anyone

277
00:13:42,240 --> 00:13:45,040
Speaker 4: know that ultimately this is where does it go from there?

278
00:13:45,160 --> 00:13:47,760
Speaker 4: What's the evidence that this is uh, you know, produce

279
00:13:47,760 --> 00:13:51,200
Speaker 4: as drugs or find new combinations of molecules faster than

280
00:13:51,280 --> 00:13:52,120
Speaker 4: traditional routes.

281
00:13:53,360 --> 00:13:56,000
Speaker 2: Well, when he was doing it, yeah, kind of in

282
00:13:56,080 --> 00:13:57,960
Speaker 2: the audience, you have to assume that there are some

283
00:13:58,000 --> 00:14:01,560
Speaker 2: people that know biochemistry, and they got.

284
00:14:01,400 --> 00:14:04,080
Speaker 3: Into some stuff that you know, I couldn't really follow,

285
00:14:04,120 --> 00:14:06,320
Speaker 3: but he was talking about how, oh you know, if

286
00:14:06,440 --> 00:14:08,560
Speaker 3: there are any chemists in the audience, you'll recognize this

287
00:14:08,640 --> 00:14:11,960
Speaker 3: drug looks a lot like this drug. And basically they

288
00:14:12,559 --> 00:14:15,440
Speaker 3: went through the whole I mean, the thing is I

289
00:14:15,520 --> 00:14:17,320
Speaker 3: dropped out of at school, right, so, like I could

290
00:14:17,360 --> 00:14:21,520
Speaker 3: find very limited amount of time. But I think the

291
00:14:21,560 --> 00:14:24,440
Speaker 3: main point that they were getting across was that in

292
00:14:24,480 --> 00:14:28,800
Speaker 3: biotech and biopharmat they spend so much time and money

293
00:14:29,240 --> 00:14:32,640
Speaker 3: on things that might just not work. And if you

294
00:14:32,720 --> 00:14:36,360
Speaker 3: have a program that can basically make you faster to fail.

295
00:14:36,320 --> 00:14:37,880
Speaker 2: Right, where you're.

296
00:14:38,160 --> 00:14:40,720
Speaker 3: Kind of figuring out what's going to be a waste

297
00:14:40,720 --> 00:14:43,000
Speaker 3: of time and what might not be more effectively.

298
00:14:43,200 --> 00:14:44,800
Speaker 2: That's huge, right.

299
00:14:44,920 --> 00:14:47,280
Speaker 3: Maybe maybe it's not that this is going to find

300
00:14:47,480 --> 00:14:50,360
Speaker 3: the cure for cancer, but the company that you know

301
00:14:50,680 --> 00:14:53,360
Speaker 3: eventually does find the cure for cancer, they're going to

302
00:14:53,400 --> 00:14:55,080
Speaker 3: be a lot more efficient with it because they're not

303
00:14:55,120 --> 00:14:57,160
Speaker 3: going to be wasting their time on stuff that you know,

304
00:14:57,200 --> 00:14:59,480
Speaker 3: maybe this program can tell them obviously won't work.

305
00:15:00,040 --> 00:15:03,080
Speaker 1: Often are people mentioning AI in general at that conference?

306
00:15:03,120 --> 00:15:05,760
Speaker 1: I'm curious if it's sort of like infiltrating to the

307
00:15:05,800 --> 00:15:10,080
Speaker 1: degree that it seems to be in financials conferences for instance.

308
00:15:10,520 --> 00:15:12,440
Speaker 3: Oh yeah, it was a ton I mean, you know,

309
00:15:12,680 --> 00:15:15,560
Speaker 3: Lily didn't mention AI. Nova didn't mention AI. They had

310
00:15:15,640 --> 00:15:18,120
Speaker 3: their own thing. But then you know you had Sonofi

311
00:15:18,440 --> 00:15:21,560
Speaker 3: and Jen both talking about their new AI platforms, and

312
00:15:21,600 --> 00:15:24,560
Speaker 3: then Video was here. Right then Video presented here and

313
00:15:24,960 --> 00:15:28,880
Speaker 3: had a whole thing about their predictive analytics platform and

314
00:15:29,000 --> 00:15:32,520
Speaker 3: Boonemo and it was I mean, you guys should have

315
00:15:32,600 --> 00:15:38,600
Speaker 3: seen when the presenter from Nvidia concluded her speech, it

316
00:15:38,680 --> 00:15:41,640
Speaker 3: was like Night of the Walking Debt. Literally, the entire

317
00:15:41,680 --> 00:15:44,440
Speaker 3: audience just like shambling up, like just trying to get

318
00:15:44,480 --> 00:15:46,600
Speaker 3: a little bit of the in Vidia magic on speak.

319
00:15:48,840 --> 00:15:51,720
Speaker 1: Oh, that's always the most awkward moment at conferences when

320
00:15:51,720 --> 00:15:54,040
Speaker 1: the speakers get off stage and everyone kind of like

321
00:15:54,120 --> 00:15:57,600
Speaker 1: awkwardly stands around waiting for their chance to introduce themselves

322
00:15:57,640 --> 00:15:58,600
Speaker 1: in network.

323
00:15:58,320 --> 00:16:02,600
Speaker 4: Hand them MACR about their company. Yes, totally.

324
00:16:02,880 --> 00:16:04,760
Speaker 2: Yeah, I was worried it was going to get violent,

325
00:16:04,800 --> 00:16:04,880
Speaker 2: you know.

326
00:16:05,040 --> 00:16:08,160
Speaker 3: And like the other thing, the ratio is at these conferences,

327
00:16:08,280 --> 00:16:10,600
Speaker 3: like finance conferences not great and like this is like

328
00:16:10,640 --> 00:16:13,480
Speaker 3: a woman with ninety men and two women just send

329
00:16:13,720 --> 00:16:16,920
Speaker 3: That was like it was like not the coolest scene.

330
00:16:17,760 --> 00:16:20,160
Speaker 4: By the way, Tracy, you know what stock is at

331
00:16:20,360 --> 00:16:23,000
Speaker 4: basically the same level it was ten years ago.

332
00:16:23,480 --> 00:16:25,360
Speaker 1: I have no idea Pfizer.

333
00:16:26,080 --> 00:16:28,800
Speaker 4: Oh that's one company that my understanding is is not

334
00:16:29,040 --> 00:16:31,760
Speaker 4: in the game at all. On GOLP one. Of course,

335
00:16:31,760 --> 00:16:34,160
Speaker 4: it went nuts in twenty twenty one. Yeah, the hot

336
00:16:34,240 --> 00:16:38,080
Speaker 4: thing was COVID injections. But obviously I think many fewer

337
00:16:38,160 --> 00:16:41,200
Speaker 4: people these days are getting boosters than may people may

338
00:16:41,240 --> 00:16:43,720
Speaker 4: have expected two years ago. And that stock is literally

339
00:16:43,720 --> 00:16:45,600
Speaker 4: where it was. No, maybe it's paid dividend and stuff

340
00:16:45,600 --> 00:16:48,160
Speaker 4: since then. That's not literally where it was in twenty fourteen,

341
00:16:48,840 --> 00:16:50,920
Speaker 4: So don't miss the golp one.

342
00:16:51,640 --> 00:16:55,600
Speaker 2: Pfizer had an oral g g golp one and you know,

343
00:16:55,680 --> 00:16:57,440
Speaker 2: ditched it. The side effects were just too bad.

344
00:16:57,480 --> 00:16:59,440
Speaker 3: And that's that's gonna be like a serious risk to

345
00:16:59,440 --> 00:17:02,880
Speaker 3: look out for, right because you know, with the oral

346
00:17:02,920 --> 00:17:05,960
Speaker 3: preparations of these like peptides or like any really like

347
00:17:06,080 --> 00:17:09,280
Speaker 3: endocrine drug, there's always it seems at least, you know,

348
00:17:09,320 --> 00:17:10,639
Speaker 3: I don't have science to back this up, but it

349
00:17:10,640 --> 00:17:12,520
Speaker 3: seems like when you have an endocrine drug and you're

350
00:17:13,040 --> 00:17:15,399
Speaker 3: trying to turn it into an oral instead of you know,

351
00:17:15,400 --> 00:17:19,080
Speaker 3: an injectable, the side effects get really crazy. And that's

352
00:17:19,119 --> 00:17:23,000
Speaker 3: definitely I think the biggest risk to like lily Novo

353
00:17:23,480 --> 00:17:26,560
Speaker 3: would be one of them gets the oral and the

354
00:17:26,640 --> 00:17:29,680
Speaker 3: other one has side effects that are way too bad,

355
00:17:29,920 --> 00:17:32,600
Speaker 3: right because, like I said in the beginning, right that

356
00:17:32,680 --> 00:17:35,160
Speaker 3: the oral drug will make it so that they can

357
00:17:35,200 --> 00:17:38,280
Speaker 3: take advantage of this huge demand right there. They're constrained

358
00:17:38,280 --> 00:17:40,320
Speaker 3: by supply, but the supply.

359
00:17:40,080 --> 00:17:43,280
Speaker 2: Of the oral drug would you know, kind of alleviate that.

360
00:17:43,480 --> 00:17:45,480
Speaker 3: And if one of them has it then the other

361
00:17:45,520 --> 00:17:48,040
Speaker 3: one doesn't, that could really change the landscape.

362
00:17:48,440 --> 00:17:51,919
Speaker 1: So James, in addition to bringing us dispatches from the

363
00:17:51,960 --> 00:17:55,199
Speaker 1: JPM healthcare conference and being our sort of eyes on

364
00:17:55,240 --> 00:17:58,440
Speaker 1: the ground or sunglasses on the ground. Maybe what else

365
00:17:58,440 --> 00:17:59,960
Speaker 1: are you going to do in San Francisco? Like, who

366
00:18:00,000 --> 00:18:01,320
Speaker 1: are you talking to while you're there?

367
00:18:02,119 --> 00:18:02,320
Speaker 2: Oh?

368
00:18:02,359 --> 00:18:05,199
Speaker 3: You know, I I message all the people that I

369
00:18:05,280 --> 00:18:09,320
Speaker 3: know that have a kind of venture capital healthcare vibe.

370
00:18:09,359 --> 00:18:13,159
Speaker 3: And I'm not really super involved, Like I just like

371
00:18:13,240 --> 00:18:16,520
Speaker 3: trade and you know, I'm in my own office and

372
00:18:16,520 --> 00:18:18,960
Speaker 3: trading and I'm not super linked up with all the

373
00:18:18,960 --> 00:18:20,840
Speaker 3: finance people. So I didn't get invited to any of

374
00:18:20,920 --> 00:18:23,400
Speaker 3: the like events or anything. But you know, I can

375
00:18:23,440 --> 00:18:25,800
Speaker 3: still have a good time in San Francisco myself.

376
00:18:26,680 --> 00:18:28,879
Speaker 1: James, I think that's it. Oh yeah, go ahead.

377
00:18:29,480 --> 00:18:32,560
Speaker 2: I just want to say, Joe, well you are a

378
00:18:32,560 --> 00:18:33,440
Speaker 2: really musician.

379
00:18:34,080 --> 00:18:37,200
Speaker 4: Finally, finally a little respector on here. No, I appreciate

380
00:18:37,240 --> 00:18:40,400
Speaker 4: that I met James in person at our concert in December.

381
00:18:41,040 --> 00:18:42,679
Speaker 4: Very kind of you to say, on are thank you

382
00:18:42,680 --> 00:18:43,040
Speaker 4: so much.

383
00:18:43,840 --> 00:18:46,159
Speaker 2: I was surprised. Was I kind of expected it was

384
00:18:46,160 --> 00:18:47,080
Speaker 2: a joke, but you are.

385
00:18:48,640 --> 00:18:51,480
Speaker 4: Very very nice of you to say. Great, let's leave

386
00:18:51,520 --> 00:18:53,000
Speaker 4: it here. This is a great place to end it

387
00:18:53,040 --> 00:18:54,920
Speaker 4: on this note I love let's leave it here. There's

388
00:18:54,920 --> 00:18:56,560
Speaker 4: a great place to end. He kind of broke up

389
00:18:56,560 --> 00:18:57,560
Speaker 4: there at the end, so I don't know if we

390
00:18:57,640 --> 00:18:59,720
Speaker 4: got that on audio. I think I heard it.

391
00:19:00,960 --> 00:19:02,040
Speaker 2: I heard it, I heard it.

392
00:19:06,640 --> 00:19:09,760
Speaker 4: Lots More is produced by Carmen Rodriguez and Dashel Bennett,

393
00:19:09,800 --> 00:19:12,920
Speaker 4: with help from Moses Ondam and kil Brooks. Our sound

394
00:19:13,000 --> 00:19:15,760
Speaker 4: engineer is Blake Maples. Sage Bauman is the head of

395
00:19:15,760 --> 00:19:16,920
Speaker 4: Bloomberg Podcasts.

396
00:19:17,160 --> 00:19:20,320
Speaker 1: Please rate, review, and subscribe to Odd, Lots and Lots

397
00:19:20,320 --> 00:19:24,080
Speaker 1: More on your favorite podcast platforms, and remember that Bloomberg

398
00:19:24,080 --> 00:19:27,160
Speaker 1: subscribers can listen to all our podcasts ad free by

399
00:19:27,240 --> 00:19:34,160
Speaker 1: connecting through Apple Podcasts. Thanks for listening. It's drug GPT

400
00:19:34,440 --> 00:19:35,360
Speaker 1: Joe Oh